Syndax Pharmaceuticals (SNDX) Halts Axatilimab IPF Program After Phase 2 Miss
Syndax Pharmaceuticals (SNDX) halted its axatilimab IPF program after the Phase 2 MAXPIRe trial missed its primary endpoint. The company will not pursue IPF development, but ongoing cGVHD trials remain unaffected. Safety results were comparable to placebo.
How this was made
The 30-second read
Why it matters
The trial failure removes a potential revenue stream and may delay cash flow expectations.
Market read
The announcement is a primary disclosure of a failed Phase 2 trial, likely prompting a sell‑off in SNDX.
What to watch
The company retains its cGVHD program, which could offset the IPF setback if results are positive.
Background
Syndax Pharmaceuticals (NASDAQ:SNDX) is a clinical‑stage biotech focused on immunology and fibrosis therapies.
Ticker impact
Syndax announced its Phase 2 axatilimab trial in IPF failed to meet the primary endpoint and the program is being halted.
likely downward pressure as investors price in the trial failure
Phase 2 failure is material for a biotech and typically triggers a sell‑off.
Market effects
May dampen sentiment for IPF and related fibrosis therapeutics.
Limited to US biotech sector.
Minimal beyond niche biotech investors.
Counterpoint
If cGVHD data later proves strong, the overall pipeline could still support the stock.
Key entities
- companySyndax Pharmaceuticals
Biotech developer of axatilimab.
